US1017286A
(en)
|
1909-03-01 |
1912-02-13 |
Du Pont Powder Co |
Apparatus for treating explosive powder.
|
US1013712A
(en)
|
1911-06-03 |
1912-01-02 |
Alfred D Williams |
Tie and rail-fastener.
|
EP0009517A1
(en)
|
1978-10-04 |
1980-04-16 |
THE PROCTER & GAMBLE COMPANY |
Vaginal contraceptive
|
NZ234143A
(en)
|
1989-06-28 |
1991-10-25 |
Mcneil Ppc Inc |
Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
|
PL180717B1
(pl)
|
1993-11-30 |
2001-03-30 |
Searle & Co |
N o w e 1 -[4-(aminosulfonylo)fenylo]pirazolilobenzenosulfonamidy do leczenia stanów zapalnych PL PL PL PL PL PL PL
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5844092A
(en)
|
1994-03-18 |
1998-12-01 |
Genentech, Inc. |
Human TRK receptors and neurotrophic factor inhibitors
|
US5430021A
(en)
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
US6677135B1
(en)
|
1996-05-08 |
2004-01-13 |
Biogen, Inc. |
Ret ligand (RetL) for stimulating neutral and renal growth
|
CN1163509C
(zh)
|
1996-05-08 |
2004-08-25 |
拜奥根有限公司 |
刺激神经和肾生长的RET配体(RetL)
|
CA2206201A1
(en)
|
1996-05-29 |
1997-11-29 |
Yoshiaki Isobe |
Pyrazole derivatives and their pharmaceutical use
|
US6682921B1
(en)
|
1996-08-21 |
2004-01-27 |
New York University |
Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
|
JP3898296B2
(ja)
|
1996-08-28 |
2007-03-28 |
ポーラ化成工業株式会社 |
ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬
|
DE69827786T2
(de)
|
1997-04-25 |
2005-11-24 |
Takeda Pharmaceutical Co. Ltd. |
Condensierte pyridazine derivate,deren herstellung und verwendung
|
US6531152B1
(en)
|
1998-09-30 |
2003-03-11 |
Dexcel Pharma Technologies Ltd. |
Immediate release gastrointestinal drug delivery system
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
AU7103900A
(en)
|
1999-09-01 |
2001-03-26 |
Biogen, Inc. |
Ret ligand 5 (retl5) compositions and uses thereof
|
US6534085B1
(en)
|
1999-09-23 |
2003-03-18 |
Bioresponse L.L.C. |
Phytochemicals for promoting weight loss
|
ATE396023T1
(de)
*
|
2000-01-24 |
2008-06-15 |
Graniterie Petitjean Sas |
Zwischenplatte zum einsetzen in einem schneidschlitz
|
FI20000403A0
(fi)
|
2000-02-22 |
2000-02-22 |
Hannu Sariola |
GDNF perhesukuisten yhdisteiden käyttö kivessyövän hoitoon tarkoitettujen tuotteiden valmistamiseksi
|
IL153375A0
(en)
|
2000-06-22 |
2003-07-06 |
Genentech Inc |
Agonist anti-trk-c monoclonal antibodies
|
TWI312347B
(en)
|
2001-02-08 |
2009-07-21 |
Eisai R&D Man Co Ltd |
Bicyclic nitrogen-containing condensed ring compounds
|
CA2448956C
(en)
|
2001-05-30 |
2017-10-03 |
Genentech, Inc. |
Anti-ngf antibodies for the treatment of various disorders
|
AU2002334355A1
(en)
|
2001-09-06 |
2003-03-18 |
Prochon Biotech Ltd. |
Protein tyrosine kinase inhibitors
|
US7101572B2
(en)
|
2001-12-07 |
2006-09-05 |
Unilab Pharmatech, Ltd. |
Taste masked aqueous liquid pharmaceutical composition
|
US20030199525A1
(en)
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
KR20040097375A
(ko)
|
2002-04-23 |
2004-11-17 |
시오노기 앤드 컴파니, 리미티드 |
피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
|
US7449488B2
(en)
|
2002-06-04 |
2008-11-11 |
Schering Corporation |
Pyrazolopyrimidines as protein kinase inhibitors
|
ITMI20021620A1
(it)
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
CA2493000A1
(en)
|
2002-07-24 |
2004-01-29 |
University Of Cincinnati |
4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
|
JP4024624B2
(ja)
|
2002-08-26 |
2007-12-19 |
富士通株式会社 |
半導体装置の製造方法及び製造装置
|
US7196078B2
(en)
|
2002-09-04 |
2007-03-27 |
Schering Corpoartion |
Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US7119200B2
(en)
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
DK1537116T3
(da)
|
2002-09-04 |
2010-09-27 |
Schering Corp |
Pyrazolopyrimidiner egnede til behandling af cancersygdomme
|
WO2004052315A2
(en)
|
2002-12-11 |
2004-06-24 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
AU2003298942A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO2004074244A2
(en)
|
2003-02-20 |
2004-09-02 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
WO2004082458A2
(en)
|
2003-02-21 |
2004-09-30 |
The Johns Hopkins University |
Tyrosine kinome
|
JP2004277337A
(ja)
|
2003-03-14 |
2004-10-07 |
Sumitomo Pharmaceut Co Ltd |
ピラゾロ[1,5−a]ピリミジン誘導体
|
EP1608652A1
(en)
|
2003-03-31 |
2005-12-28 |
Vernalis (Cambridge) Limited |
Pyrazolopyrimidine compounds and their use in medicine
|
WO2004089415A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
|
WO2004089471A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
|
US20060094699A1
(en)
|
2003-04-11 |
2006-05-04 |
Kampen Gita Camilla T |
Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
|
AU2004234286A1
(en)
|
2003-04-28 |
2004-11-11 |
Galpharma Co., Ltd |
Galectin 9-inducing factor
|
PA8603801A1
(es)
|
2003-05-27 |
2004-12-16 |
Janssen Pharmaceutica Nv |
Derivados de la quinazolina
|
JP2005008581A
(ja)
|
2003-06-20 |
2005-01-13 |
Kissei Pharmaceut Co Ltd |
新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
|
EA009517B1
(ru)
|
2003-06-27 |
2008-02-28 |
Байер Кропсайенс Аг |
Пиразолопиримидины
|
JP4489077B2
(ja)
|
2003-07-15 |
2010-06-23 |
アムジェン インコーポレイテッド |
選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体
|
US20090143399A1
(en)
|
2003-10-14 |
2009-06-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Protein Kinase Inhibitors
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
EP1682564A1
(en)
|
2003-10-27 |
2006-07-26 |
Genelabs Technologies, Inc. |
METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES
|
MY141220A
(en)
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
BRPI0416801A
(pt)
|
2003-11-21 |
2007-01-09 |
Novartis Ag |
derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
|
RU2006122853A
(ru)
|
2003-11-28 |
2008-01-10 |
Новартис АГ (CH) |
Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
|
UA83881C2
(en)
|
2003-12-18 |
2008-08-26 |
Янссен Фармацевтика Н.В. |
Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
|
WO2005062795A2
(en)
|
2003-12-19 |
2005-07-14 |
Plexxikon, Inc. |
Compounds and methods for development of ret modulators
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
GB0330042D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
|
WO2005068424A1
(en)
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
PE20051089A1
(es)
|
2004-01-22 |
2006-01-25 |
Novartis Ag |
Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
|
US20050222171A1
(en)
|
2004-01-22 |
2005-10-06 |
Guido Bold |
Organic compounds
|
WO2005099363A2
(en)
|
2004-03-26 |
2005-10-27 |
Whitehead Institute For Biomedical Research |
Methods of diagnosing, preventing and treating cancer metastasis
|
UA91677C2
(ru)
|
2004-03-30 |
2010-08-25 |
Интермюн, Инк. |
Макроциклические соединения как ингибиторы вирусной репликации
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
AR050365A1
(es)
|
2004-08-02 |
2006-10-18 |
Osi Pharm Inc |
Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
|
PE20060664A1
(es)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
Amidas biciclicas como inhibidores de cinasa
|
WO2006050076A1
(en)
|
2004-10-29 |
2006-05-11 |
Janssen Pharmaceutica, N.V. |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
ZA200704476B
(en)
|
2004-11-04 |
2008-09-25 |
Vertex Pharma |
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
|
JO3088B1
(ar)
|
2004-12-08 |
2017-03-15 |
Janssen Pharmaceutica Nv |
مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
|
DE102005003687A1
(de)
|
2005-01-26 |
2006-07-27 |
Sphingo Tec Gmbh |
Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
CN101119996A
(zh)
|
2005-02-16 |
2008-02-06 |
阿斯利康(瑞典)有限公司 |
化学化合物
|
PT1853602E
(pt)
|
2005-02-16 |
2010-08-25 |
Astrazeneca Ab |
Compostos químicos
|
EP1848506A2
(en)
|
2005-02-18 |
2007-10-31 |
Attenuon, LLC |
Pyrimidine-fused diazepine derivatives and indole-fused pteridines
|
EA012393B1
(ru)
|
2005-03-21 |
2009-10-30 |
Эли Лилли Энд Компани |
Имидазопиридазиновые соединения
|
GB0507575D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
US7402579B2
(en)
|
2005-04-15 |
2008-07-22 |
Cylene Pharmaceuticals, Inc. |
Quinobenzoxazine analogs and compositions
|
WO2006115452A1
(en)
|
2005-04-27 |
2006-11-02 |
Astrazeneca Ab |
Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
|
WO2006123113A2
(en)
|
2005-05-16 |
2006-11-23 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
WO2006128042A2
(en)
|
2005-05-26 |
2006-11-30 |
The Johns Hopkins University |
Methods of identifying mutations in nucleic acid
|
CA2650999A1
(en)
|
2005-05-31 |
2006-12-07 |
The Pfahl Family Trust (Dated 9 July 1996) |
Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
|
WO2006130673A1
(en)
|
2005-05-31 |
2006-12-07 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
|
CN100406650C
(zh)
|
2005-06-05 |
2008-07-30 |
徐斌 |
一种抗特大变位的模块式梳型桥梁伸缩缝装置
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
AU2006261993B2
(en)
|
2005-06-22 |
2011-11-17 |
Plexxikon, Inc. |
Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors
|
US20070025540A1
(en)
|
2005-07-07 |
2007-02-01 |
Roger Travis |
Call center routing based on talkativeness
|
GB0515026D0
(en)
|
2005-07-21 |
2005-08-31 |
Novartis Ag |
Organic compounds
|
CN101263156A
(zh)
|
2005-07-25 |
2008-09-10 |
因特蒙公司 |
C型肝炎病毒复制的新颖大环抑制剂
|
EP1910369A1
(en)
|
2005-07-29 |
2008-04-16 |
Astellas Pharma Inc. |
Fused heterocycles as lck inhibitors
|
JP2009503071A
(ja)
|
2005-08-03 |
2009-01-29 |
イーストマン ケミカル カンパニー |
トコフェリルポリエチレングリコールスクシネート粉末及びその製造方法
|
AU2006283592A1
(en)
|
2005-08-22 |
2007-03-01 |
Amgen Inc. |
Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
|
WO2007025090A2
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
|
EA017318B1
(ru)
|
2005-08-25 |
2012-11-30 |
Креабилис Терапеутикс С.П.А. |
Полимерные конъюгаты индолокарбазола и его производных
|
DE102005042742A1
(de)
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
US20070078136A1
(en)
|
2005-09-22 |
2007-04-05 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
JP5152922B2
(ja)
|
2005-10-06 |
2013-02-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
|
EP1931675B1
(en)
|
2005-10-06 |
2015-01-14 |
Merck Sharp & Dohme Corp. |
Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors
|
ATE519757T1
(de)
|
2005-10-11 |
2011-08-15 |
Centre Nat Rech Scient |
3 hydroxyflavon-derivate zur erkennung und quantifizierung von zell-apoptosen
|
DK1999129T3
(da)
|
2005-10-11 |
2011-02-07 |
Intermune Inc |
Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
|
US8101625B2
(en)
|
2005-10-21 |
2012-01-24 |
Exelixis, Inc. |
Pyrimidinones as Casein Kinase II (CK2) modulators
|
JP2009519218A
(ja)
|
2005-11-03 |
2009-05-14 |
エスジーエックス ファーマシューティカルズ、インコーポレイテッド |
ピリミジニル−チオフェンキナーゼモジュレータ
|
US20070149523A1
(en)
|
2005-11-14 |
2007-06-28 |
Jan Ehlert |
Thiazole Analogues and Uses Thereof
|
EP1785420A1
(en)
|
2005-11-14 |
2007-05-16 |
4Sc Ag |
Thiazole analogues and uses thereof
|
WO2007057399A2
(en)
|
2005-11-15 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Treatment of cancer with indole derivatives
|
WO2007057397A1
(en)
|
2005-11-15 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Treatment of cancer
|
GB0524436D0
(en)
|
2005-11-30 |
2006-01-11 |
Novartis Ag |
Organic compounds
|
EP1963316A2
(en)
|
2005-12-08 |
2008-09-03 |
Novartis AG |
Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
|
US8399442B2
(en)
|
2005-12-30 |
2013-03-19 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
WO2007084815A2
(en)
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica, N.V. |
Substituted thienopyrimidine kinase inhibitors
|
WO2007087245A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Ret tyrosine kinase inhibition
|
CA2636701C
(en)
|
2006-01-27 |
2014-08-05 |
Shanghai Hengrui Pharmaceutical Co. Ltd. |
Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
|
KR100846988B1
(ko)
|
2006-03-06 |
2008-07-16 |
제일약품주식회사 |
신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
|
CA2645137A1
(en)
|
2006-03-07 |
2007-09-13 |
James F. Blake |
Heterobicyclic pyrazole compounds and methods of use
|
JP2009530288A
(ja)
|
2006-03-16 |
2009-08-27 |
ノバルティス アクチエンゲゼルシャフト |
特に黒色腫の処置のためのヘテロ環式有機化合物
|
PL2001892T3
(pl)
|
2006-03-17 |
2013-09-30 |
Ambit Biosciences Corp |
Imidazolotiazolowe związki do leczenia chorób proliferacyjnych
|
NZ572202A
(en)
|
2006-03-27 |
2012-05-25 |
Nerviano Medical Sciences Srl |
Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
|
GB0606805D0
(en)
|
2006-04-04 |
2006-05-17 |
Novartis Ag |
Organic compounds
|
BRPI0710874A2
(pt)
|
2006-04-26 |
2012-02-14 |
Hoffmann La Roche |
compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
|
CA2650611A1
(en)
|
2006-05-15 |
2007-11-29 |
Irm Llc |
Compositions and methods for fgf receptor kinases inhibitors
|
US20090209580A1
(en)
|
2006-05-18 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
EP1873157A1
(en)
|
2006-06-21 |
2008-01-02 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
|
TW201345908A
(zh)
|
2006-07-05 |
2013-11-16 |
Mitsubishi Tanabe Pharma Corp |
吡唑并〔1,5-a〕嘧啶化合物
|
JPWO2008016131A1
(ja)
|
2006-08-04 |
2009-12-24 |
武田薬品工業株式会社 |
縮合複素環化合物
|
US7531539B2
(en)
|
2006-08-09 |
2009-05-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
US20110021513A1
(en)
|
2006-09-07 |
2011-01-27 |
Biogen Idec Ma Inc. |
Modulators of interleukin-1 receptor-associated kinase
|
US20110195072A1
(en)
|
2006-09-12 |
2011-08-11 |
Anne Boulay |
Non-neuroendocrine cancer therapy
|
WO2008033562A2
(en)
|
2006-09-15 |
2008-03-20 |
Xcovery, Inc. |
Kinase inhibitor compounds
|
CN101516885A
(zh)
|
2006-09-29 |
2009-08-26 |
诺瓦提斯公司 |
作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
|
US20120225057A1
(en)
|
2006-10-11 |
2012-09-06 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
BRPI0718266A2
(pt)
|
2006-10-30 |
2014-01-07 |
Novartis Ag |
Compostos heterocíclicos como agentes anti-inflamatórios.
|
EP1918291A1
(en)
|
2006-10-30 |
2008-05-07 |
Novartis AG |
3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
|
BRPI0718029A2
(pt)
|
2006-11-06 |
2013-11-26 |
Supergen Inc |
Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
|
ES2645947T3
(es)
|
2006-11-15 |
2017-12-11 |
Ym Biosciences Australia Pty Ltd |
Inhibidores de actividad de quinasa
|
PE20121126A1
(es)
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
JP2010514695A
(ja)
|
2006-12-21 |
2010-05-06 |
プレキシコン,インコーポレーテッド |
キナーゼ調節のための化合物および方法およびそのための適応症
|
WO2008079909A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
US20080199426A1
(en)
|
2007-01-11 |
2008-08-21 |
Sukhatme Vikas P |
Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
|
WO2008089388A2
(en)
|
2007-01-19 |
2008-07-24 |
Bayer Healthcare Llc |
Treatment of cancers having resistance to chemotherapeutic agents
|
US20080234267A1
(en)
|
2007-03-20 |
2008-09-25 |
Karen Elizabeth Lackey |
Compounds and Methods of Treatment
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
EP2137187A1
(en)
|
2007-03-28 |
2009-12-30 |
Inovacia AB |
Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
|
UA101611C2
(ru)
|
2007-04-03 |
2013-04-25 |
Аррей Байофарма Инк. |
СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
|
US20110189167A1
(en)
|
2007-04-20 |
2011-08-04 |
Flynn Daniel L |
Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
|
JP5160637B2
(ja)
|
2007-05-04 |
2013-03-13 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
c−kitおよびPDGFRキナーゼインヒビターとしての化合物および組成物
|
WO2008138184A1
(fr)
|
2007-05-14 |
2008-11-20 |
Shanghai Hengrui Pharmaceutical Co.Ltd. |
Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
|
DK2170827T3
(da)
|
2007-06-21 |
2013-11-18 |
Janssen Pharmaceutica Nv |
Indolin-2-oner og aza-indolin-2-oner
|
US20090012045A1
(en)
|
2007-06-26 |
2009-01-08 |
Rigel Pharmaceuticals, Inc. |
Methods of Treating Cell Proliferative Disorders
|
AU2008273889B2
(en)
|
2007-07-09 |
2012-03-08 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
WO2009012262A1
(en)
|
2007-07-16 |
2009-01-22 |
The Regents Of The University Of California |
Protein kinase modulating compounds and methods for making and using them
|
WO2009012283A1
(en)
|
2007-07-17 |
2009-01-22 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CA2693967A1
(en)
|
2007-07-19 |
2009-01-29 |
Schering Corporation |
Heterocyclic amide compounds as protein kinase inhibitors
|
CA2693901C
(en)
|
2007-07-20 |
2015-12-29 |
Nerviano Medical Sciences S.R.L. |
Substituted indazole derivatives active as kinase inhibitors
|
WO2009017838A2
(en)
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
DK2185698T3
(en)
|
2007-08-07 |
2015-07-27 |
Purdue Research Foundation |
Kinase Inhibitors and Uses thereof
|
ME02239B
(me)
|
2007-08-10 |
2015-04-30 |
Regeneron Pharma |
Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
|
EP2025678A1
(en)
|
2007-08-17 |
2009-02-18 |
Oncalis AG |
Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
|
WO2009042646A1
(en)
|
2007-09-24 |
2009-04-02 |
Curis, Inc. |
Anti-proliferative agents
|
AU2008312631A1
(en)
|
2007-10-16 |
2009-04-23 |
Wyeth Llc |
Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
|
EA201000603A1
(ru)
|
2007-10-23 |
2010-12-30 |
Новартис Аг |
ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
|
WO2009060197A1
(en)
|
2007-11-08 |
2009-05-14 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazopyridazines for use as protein kinase inhibitors
|
CA2706946A1
(en)
|
2007-11-28 |
2009-06-04 |
Schering Corporation |
2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
|
WO2009071480A2
(en)
|
2007-12-04 |
2009-06-11 |
Nerviano Medical Sciences S.R.L. |
Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
|
EP2235062A1
(en)
|
2008-01-17 |
2010-10-06 |
Irm Llc |
Improved anti-trkb antibodies
|
US20090227556A1
(en)
|
2008-01-31 |
2009-09-10 |
Eisai R&D Management Co., Ltd. |
Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
|
TW200938542A
(en)
|
2008-02-01 |
2009-09-16 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
US20090209496A1
(en)
|
2008-02-15 |
2009-08-20 |
David Chaplin |
Methods and compositions for enhancing the efficacy of rtk inhibitors
|
DK2262807T3
(en)
|
2008-03-19 |
2015-11-30 |
Chembridge Corp |
NOVEL tyrosine kinase inhibitors
|
EP2254886B1
(en)
|
2008-03-28 |
2016-05-25 |
Nerviano Medical Sciences S.r.l. |
3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
KR101324804B1
(ko)
|
2008-05-13 |
2013-11-01 |
아이알엠 엘엘씨 |
키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
|
PE20091846A1
(es)
|
2008-05-19 |
2009-12-16 |
Plexxikon Inc |
DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP2282995B1
(en)
|
2008-05-23 |
2015-08-26 |
Novartis AG |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
AU2009257635A1
(en)
|
2008-06-10 |
2009-12-17 |
Plexxikon, Inc. |
5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
|
EP2303890A4
(en)
|
2008-06-19 |
2012-04-11 |
Progenics Pharm Inc |
INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
|
EP2313091A4
(en)
|
2008-07-14 |
2012-04-04 |
Univ Kingston |
PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
|
EP2323664B1
(en)
|
2008-07-29 |
2015-01-07 |
Nerviano Medical Sciences S.r.l. |
Use of a cdk inhibitor for the treatment of glioma
|
WO2010028254A2
(en)
|
2008-09-05 |
2010-03-11 |
Auspek Pharmaceuticals, Inc. |
Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
|
EP2161271A1
(en)
|
2008-09-08 |
2010-03-10 |
Università Degli Studi Di Milano - Bicocca |
Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
|
US8394802B2
(en)
|
2008-09-19 |
2013-03-12 |
Nerviano Medical Sciences S.R.L. |
3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
|
PL2350075T3
(pl)
|
2008-09-22 |
2014-07-31 |
Array Biopharma Inc |
Podstawione związki imidazo[1,2b]pirydazynowe jako inhibitory kinaz Trk
|
WO2010036629A2
(en)
|
2008-09-26 |
2010-04-01 |
National Health Research Institutes |
Fused multicyclic compounds as protein kinase inhibitors
|
US8513263B2
(en)
|
2008-10-22 |
2013-08-20 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
|
PE20131197A1
(es)
|
2008-10-31 |
2013-11-06 |
Genentech Inc |
Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
|
JP5686736B2
(ja)
|
2008-11-06 |
2015-03-18 |
アムビト ビオスシエンセス コルポラチオン |
プロテインキナーゼモジュレーターとしてのイミダゾロチアゾール化合物
|
EP2376084B1
(en)
|
2008-11-24 |
2013-07-17 |
Nerviano Medical Sciences S.r.l. |
CDK inhibitor for the treatment of mesothelioma
|
KR101061599B1
(ko)
|
2008-12-05 |
2011-09-02 |
한국과학기술연구원 |
비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
|
JO3265B1
(ar)
|
2008-12-09 |
2018-09-16 |
Novartis Ag |
مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
|
PL2881402T3
(pl)
|
2009-02-12 |
2017-10-31 |
Cell Signaling Technology Inc |
Ekspresja zmutowanej ROS w ludzkim raku wątroby
|
WO2010111527A1
(en)
|
2009-03-26 |
2010-09-30 |
Plexxikon, Inc. |
Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
|
TWI410418B
(zh)
|
2009-04-29 |
2013-10-01 |
Ind Tech Res Inst |
氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
|
PL3009428T3
(pl)
|
2009-05-08 |
2018-07-31 |
Astellas Pharma Inc. |
Diaminoheterocykliczny związek karboksyamidowy
|
EP2440058A4
(en)
|
2009-06-12 |
2012-11-21 |
Dana Farber Cancer Inst Inc |
FOUNDED HETEROCYCLIC COMPOUNDS AND USES THEREOF
|
EP3045457B1
(en)
|
2009-06-15 |
2018-05-09 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
KR101147550B1
(ko)
|
2009-10-22 |
2012-05-17 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
|
KR101116756B1
(ko)
|
2009-10-27 |
2012-03-13 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
|
WO2011053861A1
(en)
|
2009-10-29 |
2011-05-05 |
Genosco |
Kinase inhibitors
|
KR101663637B1
(ko)
|
2009-11-13 |
2016-10-07 |
제노스코 |
키나아제 억제제
|
KR101094446B1
(ko)
|
2009-11-19 |
2011-12-15 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
ES2636262T3
(es)
|
2010-01-29 |
2017-10-05 |
Hanmi Science Co., Ltd. |
Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora en las proteínas cinasas
|
KR101483215B1
(ko)
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
EP2528918B1
(en)
|
2010-01-29 |
2014-09-10 |
Nerviano Medical Sciences S.r.l. |
6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators
|
DK2536414T3
(en)
|
2010-02-18 |
2016-10-03 |
Inserm (Institut Nat De La Santé Et De La Rech Médicale) |
METHOD FOR PREVENTING cancer metastasis
|
JP2013526852A
(ja)
|
2010-04-06 |
2013-06-27 |
カリス ライフ サイエンシズ ルクセンブルク ホールディングス |
疾患に対する循環バイオマーカー
|
US8383793B2
(en)
|
2010-04-15 |
2013-02-26 |
St. Jude Children's Research Hospital |
Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
MY191934A
(en)
*
|
2010-05-20 |
2022-07-19 |
Array Biopharma Inc |
Macrocyclic compounds as trk kinase inhibitors
|
PL3333188T3
(pl)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Przeciwciała anty-ngf i ich zastosowanie
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
WO2012037155A2
(en)
|
2010-09-13 |
2012-03-22 |
Gtx, Inc. |
Tyrosine kinase inhibitors
|
WO2012047017A2
(ko)
|
2010-10-05 |
2012-04-12 |
크리스탈지노믹스(주) |
2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
|
JP2014005206A
(ja)
|
2010-10-22 |
2014-01-16 |
Astellas Pharma Inc |
アリールアミノヘテロ環カルボキサミド化合物
|
US9783601B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
US8618146B2
(en)
|
2011-01-03 |
2013-12-31 |
Dr. Reddy's Laboratories Limited |
Epothilone compound formulations
|
WO2012101029A1
(en)
|
2011-01-26 |
2012-08-02 |
Nerviano Medical Sciences S.R.L. |
Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
|
BR112013018515B1
(pt)
|
2011-01-26 |
2021-06-29 |
Nerviano Medical Sciences S.R.I |
Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
|
CN102093421B
(zh)
|
2011-01-28 |
2014-07-02 |
北京康辰药业有限公司 |
一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
AU2012214762B2
(en)
|
2011-02-07 |
2015-08-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
BR112013021537B1
(pt)
|
2011-02-24 |
2021-08-10 |
Nerviano Medical Sciences S.R.L. |
Derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
|
AP2013007103A0
(en)
|
2011-02-25 |
2013-09-30 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
US8791112B2
(en)
|
2011-03-30 |
2014-07-29 |
Arrien Pharmaceuticals Llc |
Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
|
PL2693881T3
(pl)
|
2011-04-01 |
2020-03-31 |
University Of Utah Research Foundation |
Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL
|
WO2012139930A1
(en)
|
2011-04-11 |
2012-10-18 |
Nerviano Medical Sciences S.R.L. |
Pyrazolyl-pyrimidine derivatives as kinase inhibitors
|
JP5970537B2
(ja)
|
2011-04-19 |
2016-08-17 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害薬として活性な置換ピリミジニル−ピロール
|
CA2835478C
(en)
|
2011-05-12 |
2019-02-05 |
Nerviano Medical Sciences S.R.L. |
Substituted indazole derivatives active as kinase inhibitors
|
CA2835835C
(en)
|
2011-05-13 |
2019-04-02 |
Array Biopharma Inc. |
Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
|
RU2477723C2
(ru)
|
2011-06-16 |
2013-03-20 |
Общество С Ограниченной Ответственностью "Фьюжн Фарма" |
Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
|
WO2013016720A2
(en)
|
2011-07-28 |
2013-01-31 |
Gerinda Therapeutics, Inc. |
Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
|
JP6016915B2
(ja)
|
2011-07-28 |
2016-10-26 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール
|
CN103764676A
(zh)
|
2011-08-04 |
2014-04-30 |
日本国立癌症研究中心 |
Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法
|
BR112014004213A2
(pt)
|
2011-08-23 |
2017-06-20 |
Found Medicine Inc |
novas moléculas de fusão kif5b-ret e usos das mesmas
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
WO2013036232A2
(en)
|
2011-09-08 |
2013-03-14 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
US9181258B2
(en)
|
2011-10-07 |
2015-11-10 |
Nerviano Medical Sciences S.R.L. |
Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
|
WO2013050446A1
(en)
|
2011-10-07 |
2013-04-11 |
Nerviano Medical Sciences S.R.L. |
SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
KR20140128946A
(ko)
|
2011-11-14 |
2014-11-06 |
테사로, 인코포레이티드 |
특정한 티로신 키나제의 조절
|
US20140137274A1
(en)
|
2011-11-30 |
2014-05-15 |
Lsip, Llc |
Induced malignant stem cells
|
KR20140105508A
(ko)
|
2011-12-12 |
2014-09-01 |
닥터 레디스 레보러터리즈 리미티드 |
트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US9156852B2
(en)
|
2011-12-30 |
2015-10-13 |
Hanmi Pharm. Co., Ltd |
Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases
|
JP2015109806A
(ja)
|
2012-03-22 |
2015-06-18 |
アステラス製薬株式会社 |
新規ret融合体の検出法
|
EP2842955B1
(en)
|
2012-04-26 |
2016-10-05 |
ONO Pharmaceutical Co., Ltd. |
Trk-inhibiting compound
|
JP2013226108A
(ja)
|
2012-04-27 |
2013-11-07 |
Astellas Pharma Inc |
新規ntrk2活性化変異の検出法
|
EP2849751A1
(en)
|
2012-05-10 |
2015-03-25 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
ES2751944T3
(es)
|
2012-05-23 |
2020-04-02 |
Nerviano Medical Sciences Srl |
Proceso para la preparación de N-[5-(3,5-difluoro-bencil)-1H-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida
|
TWI585088B
(zh)
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
|
KR102163776B1
(ko)
|
2012-07-11 |
2020-10-12 |
블루프린트 메디신즈 코포레이션 |
섬유아세포 성장인자 수용체의 저해제
|
WO2014017491A1
(ja)
|
2012-07-26 |
2014-01-30 |
独立行政法人国立がん研究センター |
Cep55遺伝子とret遺伝子との融合遺伝子
|
EP2689778A1
(en)
|
2012-07-27 |
2014-01-29 |
Pierre Fabre Medicament |
Derivatives of azaindoles or diazaindoles for treating pain
|
WO2014019908A2
(en)
|
2012-08-02 |
2014-02-06 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrroles active as kinases inhibitors
|
US20150218652A1
(en)
|
2012-08-31 |
2015-08-06 |
The Regents Of The Unversity Of Colorado, A Body Corporate |
Methods for diagnosis and treatment of cancer
|
EP2892532B1
(en)
|
2012-09-07 |
2019-02-13 |
Exelixis, Inc. |
Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
|
US20140084039A1
(en)
|
2012-09-24 |
2014-03-27 |
Electro Scientific Industries, Inc. |
Method and apparatus for separating workpieces
|
CA3077553C
(en)
|
2012-09-25 |
2022-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Ret inhibitor
|
JP2014082984A
(ja)
|
2012-10-23 |
2014-05-12 |
Astellas Pharma Inc |
新規ntrk2活性化変異の検出法
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
AU2013337264B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
EP2917214B1
(en)
|
2012-11-07 |
2019-08-28 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
|
AR093457A1
(es)
|
2012-11-12 |
2015-06-10 |
Cephalon Inc |
Derivados de bendamustina y metodos para utilizarlos
|
RU2677667C2
(ru)
|
2012-11-13 |
2019-01-18 |
Эррэй Биофарма Инк. |
Соединения n-пирролидинилмочевины, n'-пиразолилмочевины, тиомочевины, гуанидина и цианогуанидина как ингибиторы киназы trka
|
WO2014078408A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078417A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9790210B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
KR102181913B1
(ko)
|
2012-11-13 |
2020-11-23 |
어레이 바이오파마 인크. |
통증의 치료에 유용한 바이시클릭 유레아, 티오유레아, 구아니딘 및 시아노구아니딘 화합물
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9969694B2
(en)
|
2012-11-13 |
2018-05-15 |
Array Biopharma Inc. |
N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
CN104822390A
(zh)
|
2012-11-29 |
2015-08-05 |
耶达研究及发展有限公司 |
预防肿瘤转移、癌症治疗和预后及鉴定为推定转移抑制剂的试剂的方法
|
WO2014086284A1
(zh)
|
2012-12-04 |
2014-06-12 |
上海医药集团股份有限公司 |
一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
|
US9447135B2
(en)
|
2012-12-14 |
2016-09-20 |
University Of Kentucky Research Foundation |
Semi-synthetic mithramycin derivatives with anti-cancer activity
|
FR3000494B1
(fr)
|
2012-12-28 |
2015-08-21 |
Oribase Pharma |
Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
|
FR3000492B1
(fr)
|
2012-12-28 |
2015-09-11 |
Oribase Pharma |
Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
|
ES2696700T3
(es)
|
2012-12-28 |
2019-01-17 |
Crystalgenomics Inc |
Derivado de 2,3-dihidro-isoindol-1-on como supresor de quinasa BTK y composición farmacéutica que incluye el mismo
|
FR3000493A1
(fr)
|
2012-12-28 |
2014-07-04 |
Oribase Pharma |
Nouveaux inhibiteurs de proteines kinases
|
US9127055B2
(en)
|
2013-02-08 |
2015-09-08 |
Astellas Pharma Inc. |
Method of treating pain with anti-human NGF antibody
|
BR122017003181A2
(pt)
|
2013-02-19 |
2019-09-10 |
Ono Pharmaceutical Co |
composto inibidor de trk, composição farmacêutica e medicamento compreendendo dito composto e seu uso para profilaxia e/ou terapia de doença relacionada à trk e/ou para inibir trk
|
EP2981613A4
(en)
|
2013-02-22 |
2016-11-02 |
Boris C Bastian |
FUSION POLYNUCLEOTIDES AND FUSION POLYPEPTIDES ASSOCIATED WITH CANCER, IN PARTICULAR MELANOMA, AND THEIR USES AS THERAPEUTIC AND DIAGNOSTIC TARGETS
|
WO2014134096A1
(en)
|
2013-02-27 |
2014-09-04 |
Oregon Health & Science University |
Methods of treating cancers characterized by aberrent ros1 activity
|
JP2016515508A
(ja)
|
2013-03-15 |
2016-05-30 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
融合タンパク質及びその方法
|
WO2014150751A2
(en)
*
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Biomarkers associated with brm inhibition
|
EA029296B1
(ru)
|
2013-03-15 |
2018-03-30 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы
|
WO2014152777A2
(en)
|
2013-03-15 |
2014-09-25 |
Insight Genetics, Inc. |
Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
|
AR095308A1
(es)
|
2013-03-15 |
2015-10-07 |
Glaxosmithkline Ip Dev Ltd |
Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
|
ES2946689T3
(es)
|
2013-03-15 |
2023-07-24 |
Univ Leland Stanford Junior |
Identificación y uso de marcadores tumorales de ácido nucleico circulante
|
EP2970231A1
(en)
|
2013-03-15 |
2016-01-20 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
CN105378110A
(zh)
|
2013-04-17 |
2016-03-02 |
生命技术公司 |
与癌症相关的基因融合体和基因变异体
|
US10072298B2
(en)
|
2013-04-17 |
2018-09-11 |
Life Technologies Corporation |
Gene fusions and gene variants associated with cancer
|
WO2014184069A1
(en)
|
2013-05-14 |
2014-11-20 |
Nerviano Medical Sciences S.R.L. |
Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
|
MX2015015966A
(es)
|
2013-05-30 |
2016-04-13 |
Plexxikon Inc |
Compuestos para la modulacion de cinasas e indicaciones para los mismos.
|
CA2917735C
(en)
|
2013-07-11 |
2017-04-18 |
Betta Pharmaceuticals Co., Ltd |
Protein tyrosine kinase modulators and methods of use
|
US10705087B2
(en)
|
2013-07-26 |
2020-07-07 |
Japanese Foundation For Cancer Research |
Detection method for NTRK3 fusion
|
EP3628749A1
(en)
|
2013-07-30 |
2020-04-01 |
Blueprint Medicines Corporation |
Ntrk2 fusions
|
WO2015017528A1
(en)
|
2013-07-30 |
2015-02-05 |
Blueprint Medicines Corporation |
Pik3c2g fusions
|
US20150057335A1
(en)
|
2013-08-20 |
2015-02-26 |
National Cancer Center |
Novel fusion genes identified in lung cancer
|
MX2016002626A
(es)
|
2013-08-30 |
2016-06-06 |
Ambit Biosciences Corp |
Compuestos de biarilacetamida y metodos de uso de los mismos.
|
WO2015039006A1
(en)
|
2013-09-16 |
2015-03-19 |
The General Hospital Corporation |
Methods of treating cancer
|
AU2014337314B2
(en)
|
2013-10-17 |
2018-12-13 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to KIT
|
WO2015058129A1
(en)
|
2013-10-17 |
2015-04-23 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
MX2016004678A
(es)
|
2013-10-24 |
2017-03-10 |
Univ Georgetown |
Composiciones para el tratamiento del cancer.
|
WO2015061572A1
(en)
|
2013-10-25 |
2015-04-30 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
WO2015064621A1
(ja)
|
2013-10-29 |
2015-05-07 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
GB201321146D0
(en)
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
WO2015082887A2
(en)
|
2013-12-02 |
2015-06-11 |
Bergenbio As |
Use of kinase inhibitors
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
HRP20221518T1
(hr)
|
2014-01-24 |
2023-02-17 |
Turning Point Therapeutics, Inc. |
Diaril makrociklični spojevi kao modulatori protein kinaza
|
NZ721057A
(en)
|
2014-02-05 |
2023-04-28 |
VM Oncology LLC |
Compositions of compounds and uses thereof
|
MX2016010266A
(es)
|
2014-02-14 |
2017-02-08 |
Exelixis Inc |
Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
US20170044621A1
(en)
|
2014-04-18 |
2017-02-16 |
Blueprint Medicines Corporation |
Met fusions
|
US20170044622A1
(en)
|
2014-04-18 |
2017-02-16 |
Blueprint Medicines Corporation |
Pik3ca fusions
|
RS59286B1
(sr)
|
2014-05-15 |
2019-10-31 |
Array Biopharma Inc |
1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze
|
WO2015183836A1
(en)
|
2014-05-27 |
2015-12-03 |
Brian Haynes |
Compositions, methods, and uses related to ntrk2-tert fusions
|
WO2015183837A1
(en)
|
2014-05-27 |
2015-12-03 |
Brian Haynes |
Compositions, methods, and uses related to ntrk2-tert fusions
|
WO2015184443A1
(en)
|
2014-05-30 |
2015-12-03 |
The Regents Of The University Of Colorado |
Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
|
EP3155131B1
(en)
|
2014-06-10 |
2020-02-12 |
Blueprint Medicines Corporation |
Raf1 fusions
|
EP3155118A1
(en)
|
2014-06-10 |
2017-04-19 |
Blueprint Medicines Corporation |
Pkn1 fusions
|
US10370723B2
(en)
|
2014-07-17 |
2019-08-06 |
Blueprint Medicines Corporation |
TERT fusions
|
US10370724B2
(en)
|
2014-07-17 |
2019-08-06 |
Blueprint Medicines Corporation |
PRKC fusions
|
WO2016011141A1
(en)
|
2014-07-17 |
2016-01-21 |
Blueprint Medicines Corporation |
Fgr fusions
|
JP6665154B2
(ja)
|
2014-07-17 |
2020-03-13 |
ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド |
置換尿素誘導体及びその薬学的使用
|
US20160032404A1
(en)
*
|
2014-08-01 |
2016-02-04 |
Pharmacyclics Llc |
Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
|
US9688680B2
(en)
|
2014-08-04 |
2017-06-27 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
HUE045237T2
(hu)
|
2014-08-18 |
2019-12-30 |
Ono Pharmaceutical Co |
TRK-inhibitáló vegyület savaddíciós sója
|
RU2017111590A
(ru)
|
2014-09-08 |
2018-10-10 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида
|
CR20170094A
(es)
|
2014-09-10 |
2017-05-08 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
|
HUE044604T2
(hu)
|
2014-09-10 |
2019-11-28 |
Glaxosmithkline Ip Dev Ltd |
Piridin-származékok mint transzfekció alatt átrendezõdött (RET) kináz inhibitorok
|
TWI538914B
(zh)
|
2014-10-03 |
2016-06-21 |
國立交通大學 |
蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
KR102562866B1
(ko)
|
2014-11-14 |
2023-08-04 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
|
AU2015346046B2
(en)
|
2014-11-16 |
2020-06-25 |
Array Biopharma, Inc. |
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
|
US20170356052A1
(en)
|
2014-11-18 |
2017-12-14 |
Blueprint Medicines Corporation |
Prkacb fusions
|
AU2015365587B2
(en)
|
2014-12-15 |
2020-07-23 |
Cmg Pharmaceutical Co., Ltd. |
Fused ring heteroaryl compounds and their use as TRK inhibitors
|
US10336707B2
(en)
|
2014-12-16 |
2019-07-02 |
Eudendron S.R.L. |
Heterocyclic derivatives modulating activity of certain protein kinases
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
KR101675984B1
(ko)
|
2015-02-23 |
2016-11-14 |
한양대학교 에리카산학협력단 |
티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
|
US20180045727A1
(en)
|
2015-03-03 |
2018-02-15 |
Caris Mpi, Inc. |
Molecular profiling for cancer
|
WO2016149261A1
(en)
|
2015-03-16 |
2016-09-22 |
Personal Genome Diagnostics, Inc. |
Systems and methods for analyzing nucleic acid
|
CN108137593B
(zh)
|
2015-04-21 |
2021-01-05 |
上海交通大学医学院附属瑞金医院 |
蛋白激酶抑制剂的制备和用途
|
RU2020132040A
(ru)
|
2015-05-20 |
2020-10-12 |
Те Брод Инститьют Инк. |
Общие неоантигены
|
MA43943A
(fr)
|
2015-05-29 |
2018-12-12 |
Ignyta Inc |
Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
|
CA2988423A1
(en)
|
2015-06-01 |
2016-12-08 |
Loxo Oncology, Inc. |
Methods of diagnosing and treating cancer
|
AU2015101722A4
(en)
|
2015-06-19 |
2016-05-19 |
Macau University Of Science And Technology |
Oncogenic ros1 and alk kinase inhibitor
|
US9782400B2
(en)
*
|
2015-06-19 |
2017-10-10 |
Macau University Of Science And Technology |
Oncogenic ROS1 and ALK kinase inhibitor
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
JP6871903B2
(ja)
*
|
2015-07-02 |
2021-05-19 |
ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. |
プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
|
GB201512365D0
(en)
|
2015-07-15 |
2015-08-19 |
King S College London |
Novel therapy
|
DK3322706T3
(da)
|
2015-07-16 |
2021-02-01 |
Array Biopharma Inc |
Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
KR101766194B1
(ko)
|
2015-08-07 |
2017-08-10 |
한국과학기술연구원 |
RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
|
WO2017027883A1
(en)
|
2015-08-13 |
2017-02-16 |
San Diego State University Research Foundation |
Atropisomerism for increased kinase inhibitor selectivity
|
MA41559A
(fr)
|
2015-09-08 |
2017-12-26 |
Taiho Pharmaceutical Co Ltd |
Composé de pyrimidine condensé ou un sel de celui-ci
|
WO2017049462A1
(zh)
|
2015-09-22 |
2017-03-30 |
合肥中科普瑞昇生物医药科技有限公司 |
一类新型的flt3激酶抑制剂及其用途
|
CN105255927B
(zh)
|
2015-09-30 |
2018-07-27 |
温州医科大学附属第一医院 |
一种kiaa1217-ret融合基因
|
AU2016344058A1
(en)
|
2015-10-26 |
2018-05-17 |
Array Biopharma Inc. |
Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
|
SI3371171T1
(sl)
|
2015-11-02 |
2024-03-29 |
Blueprint Medicines Corporation |
Inhibitorji ret
|
WO2017097697A1
(en)
|
2015-12-08 |
2017-06-15 |
Boehringer Ingelheim International Gmbh |
Method using a ret fusion gene as a biomarker to select non-small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment
|
JP6871869B2
(ja)
|
2016-01-15 |
2021-05-19 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
US20170224662A1
(en)
|
2016-01-22 |
2017-08-10 |
The Medicines Company |
Aqueous Formulations and Methods of Preparation and Use Thereof
|
TWI620748B
(zh)
|
2016-02-05 |
2018-04-11 |
National Health Research Institutes |
氨基噻唑化合物及其用途
|
WO2017145050A1
(en)
|
2016-02-23 |
2017-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
|
BR112018016724B1
(pt)
|
2016-02-23 |
2024-02-20 |
Taiho Pharmaceutical Co., Ltd |
Composto de pirimidina condensado ou sal do mesmo, seus usos, inibidor de ret, agente antitumor e composição farmacêutica
|
TW201733580A
(zh)
|
2016-03-11 |
2017-10-01 |
小野藥品工業股份有限公司 |
Trk抑制劑抵抗性的癌治療劑
|
UY37155A
(es)
|
2016-03-17 |
2017-10-31 |
Blueprint Medicines Corp |
Inhibidores de ret
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
CA3019671C
(en)
|
2016-04-04 |
2024-02-20 |
Loxo Oncology, Inc. |
Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
CA3020778A1
(en)
|
2016-04-15 |
2017-10-19 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
LT3442535T
(lt)
|
2016-04-15 |
2022-10-25 |
Cancer Research Technology Limited |
Heterocikliniai junginiai kaip ret kinazės inhibitoriai
|
US20210030737A1
(en)
|
2016-04-19 |
2021-02-04 |
Exelixis, Inc. |
Triple Negative Breast Cancer Treatment Method
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
|
KR102566858B1
(ko)
|
2016-05-18 |
2023-08-11 |
어레이 바이오파마 인크. |
(s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
|
WO2017201156A1
(en)
|
2016-05-18 |
2017-11-23 |
Duke University |
Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
|
JP2019519540A
(ja)
|
2016-06-01 |
2019-07-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
肺癌患者におけるalk阻害薬療法に対する応答を予測する未分化リンパ腫キナーゼにおける新規な変異
|
WO2018017983A1
(en)
|
2016-07-22 |
2018-01-25 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to ret
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
BR112019015011A2
(pt)
|
2017-01-20 |
2020-04-28 |
Exelixis Inc |
combinações de cabozantinibe e atezolizumabe para tratar câncer
|
CN108456163A
(zh)
|
2017-02-20 |
2018-08-28 |
中国科学院上海药物研究所 |
含邻氨基杂芳环炔基的化合物及其制备方法和用途
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
MA50456A
(fr)
|
2017-10-26 |
2020-09-02 |
Array Biopharma Inc |
Formulations d'un inhibiteur de kinase trk macrocyclique
|